PHARMA SOLUTIONS
ActiveSummary
PHARMA SOLUTIONS has been active since 1999 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €158,716 and a net result of €59,656. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 39% of 3,844 sector peers (NACE 70, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Articles of association
What the company does
- DurationHow long the company exists; usually unlimited, so until it is dissolved.
- Unlimited
- Name clauseThe name the company operates under according to its articles.
- PHARMA SOLUTIONS
- Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
- One provision in the deed
Who represents it, and how
- Board ruleHow the board is made up, meets and takes decisions.
- “13, 6 jaar” (deed in Dutch)
Capital, shares and profit
- Kind of sharesWhich classes of shares exist and what rights each class carries.
- “Op naam, aandelen” (deed in Dutch)
- Transfer restrictionWhether shareholders may sell their shares freely or need approval first.
- “Gezamenlijk elk helft overnemers en overdragers, door derde geboden of bij gebrek akkoord door expert aangeduid tussen partijen volgens WVV…” (deed in Dutch)
Meetings and financial year
- Annual meetingWhen the shareholders meet each year, among other things to approve the annual accounts.
- Second Friday of June at 20:00
Oversight and winding up
- Liquidation ruleHow assets are shared after dissolution: creditors first, then shareholders.
- “Een of meer, benoeming vereffenaars” (deed in Dutch)“Alle verrichtingen vermeld in wet, bevoegdheden vereffenaars” (deed in Dutch)1 more provision on this in the deed